Email: cspc@cspc.cn
Email: cspc@cspc.cn
June 20, 2023
Sponsored by CSPC and led by Professor Wang Yongjun of Beijing Tiantan Hospital, Affiliated to Capital Medical University, the TRACE series of studies on the innovative drug Mingfule® (Recombinant Human TNK Tissue-type Plasminogen Activator for Injection, rhTNK-tPA) of CSPC were highly recognized again. On February 9, the TRACE-2 study results were published in The Lancet (IF: 202.731), one of the top authoritative international medical journals. This was the first time that cerebrovascular disease drugs with independent intellectual property rights of Chinese enterprises had been published in the top global journal, marking that the achievements of clinical studies for Chinese drug registration in the field of neurology had moved to the international arena.
